Safety and efficacy of probiotic supplementation in 8 types of inflammatory arthritis: A systematic review and meta-analysis of 34 randomized controlled trials

Zeng, Liuting; Deng, Ying; He, Qian; Yang, Kailin; Li, Jun; Wang, Xiang; Liu, Huiping; Zhu, Xiaofei; Chen, Hua

doi:10.3389/fimmu.2022.961325

Cited by 18 publications

(14 citation statements)

References 157 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, probiotic treatments, prevent the increment in intestinal permeability and bacterial translocation that accompanies the disruption of intestinal barrier function. The beneficial effect of SpA is so far controversial 7,15 . A meta‐analysis research investigated 34 RCTs and 8 types of autoimmune disease including SpA, and summarized that probiotics improved symptoms in two RCTs 15 .…”

Section: Bacteria Related Diseases Pathogenesismentioning

confidence: 99%

“…The beneficial effect of SpA is so far controversial 7,15 . A meta‐analysis research investigated 34 RCTs and 8 types of autoimmune disease including SpA, and summarized that probiotics improved symptoms in two RCTs 15 . Another pilot study of 18 patients with active SpA evaluated the therapeutic effect of Lactobacillus acidophilus and Lactobacillus salivarius and ended up with significant improvements 16 .…”

Section: Bacteria Related Diseases Pathogenesismentioning

confidence: 99%

“…7,15 A meta-analysis research investigated 34 RCTs and 8 types of autoimmune disease including SpA, and summarized that probiotics improved symptoms in two RCTs. 15 Another pilot study of 18 patients with active SpA evaluated the therapeutic effect of Lactobacillus acidophilus and Lactobacillus salivarius and ended up with significant improvements. 16 On the contrary, several RCTs revealed no benefit of applying probiotic t in standardized measures used such as BASFI, BASDAI, or ASAS core domains.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Spondyloarthritis and the microbiota: Where are we now?

Chen,

Teng,

Tsai

et al. 2024

Int J of Rheum Dis

View full text Add to dashboard Cite

Spondyloarthritis and the microbiota: Where are we now? Spondyloarthritis (SpA), a disease that has been through multiple alternations with its definition and criteria, is now classified as a spectrum of disorders. Generally speaking, SpA is now defined as two major subtypes, axial SpA (axSpA) and peripheral SpA (pSpA).Within the category of axSpA, diseases can be divided into two groups based on their radiographic findings, with and without radiographic sacroiliitis, as radiographic axSpA (r-axSpA; also known as ankylosing spondylitis) and non-radiographic axSpA (nr-axSpA) 1 respectively. Some studies also considered several subtypes as axSpA, including axial psoriatic arthritis (axPsA), axial reactive arthritis (ReA), and inflammatory bowel diseases associated with SpA (SpA-IBD). On the contrary, peripheral PsA and peripheral ReA are subtypes regarded as pSpA. 2,3 Last but not least, if seronegative arthritis does not fit the diagnostic criteria, it can be defined as undifferentiated SpA. Interestingly, another way to see this is to deem psoriasis (PsO) and IBD as comorbidities or extraarticular manifestations (EAM). 4 Other EAMs besides PsO and IBD include anterior uveitis, conduction disturbance in heart, valvular heart diseases, interstitial lung diseases, lung emphysema, lung apical fibrosis, osteoporosis, bone fractures, glomerulonephritis, and renal function impairment.In conclusion, the nature of microbiota ties greatly and closely with every aspect of SpA. Knowing the effect that microbiota exert on diseases and figuring out the way to utilize it surely will be a big step forward in medicine in our era. AUTH O R CO NTR I B UTI O N SYJC, CTT, and YFT contributed to data collection and drafting of the article. CCW provided critical feedback and direction for the manuscript and revised the article.

show abstract

Section: Bacteria Related Diseases Pathogenesismentioning

confidence: 99%

Section: Bacteria Related Diseases Pathogenesismentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Spondyloarthritis and the microbiota: Where are we now?

Chen,

Teng,

Tsai

et al. 2024

Int J of Rheum Dis

View full text Add to dashboard Cite

show abstract

“…Data supports that probiotics may restore the abnormal T cell subsets, particularly the abnormal levels of naïve CD4+T, γδT, Tfh, Treg, and Th17 cells seen in SLE [ 74 ]. In a recent meta-analysis, probiotics reduced inflammation in patients with RA, measured with C-reactive protein levels [ 75 ]. Fecal microbiota transplantation (FMT) has been considered a very effective way to restoration of the normal gut microbiome in disease and has been tried in cases of resistant Clostridium difficile infections.…”

Section: Potential Microbiome Therapeutics For Ctd-ild and Vasculitismentioning

confidence: 99%

The Role of the Microbiome in Connective-Tissue-Associated Interstitial Lung Disease and Pulmonary Vasculitis

et al. 2022

View full text Add to dashboard Cite

The microbiome can trigger and maintain immune-mediated diseases and is associated with the severity and prognosis of idiopathic pulmonary fibrosis, which is the prototype of interstitial lung diseases (ILDs). The latter can be a major cause of morbidity and mortality in patients with connective-tissue diseases (CTD). In the present review, we discuss the current evidence regarding microbiome in CTD-ILD and pulmonary vasculitis. In patients with rheumatoid arthritis (RA) the BAL microbiota is significantly less diverse and abundant, compared to healthy controls. These changes are associated with disease severity. In systemic sclerosis (SSc), gastrointestinal (GI)-dysbiosis is associated with ILD. Butyrate acid administration as a means of restoration of GI-microbiota has reduced the degree of lung fibrosis in animal models. Although related studies are scarce for SLE and Sjögren’s syndrome, studies of the gut, oral and ocular microbiome provide insights into the pathogenesis of these diseases. In ANCA-associated vasculitis, disease severity and relapses have been associated with disturbed nasal mucosa microbiota, with immunosuppressive treatment restoring the microbiome changes. The results of these studies suggest however no causal relation. More studies of the lung microbiome in CTD-ILDs are urgently needed, to provide a better understanding of the pathogenesis of these diseases.

show abstract

“…Nevertheless, they seem to offer little benefit regarding metabolic abnormalities [ 36 ]. Despite this, probiotic supplementation may restore the imbalances in some inflammatory biomarkers, or alleviate the clinical signs of chronic inflammation [ 35 , 36 , 38 , 41 , 42 , 43 ].…”

Section: Introductionmentioning

confidence: 99%

PRO-DEMET Randomized Controlled Trial on Probiotics in Depression—Pilot Study Results

et al. 2023

View full text Add to dashboard Cite

There is a pressing need to identify new treatment options for depression and its comorbidities. Depression often coexists with metabolic complications, and the two may share a pathophysiological overlap, including inflammation and microbiota changes. Microbiota interventions (e.g., probiotics) may represent a safe and easy-to-use treatment option as an adjunctive therapy in patients only partially responsive to pharmacologic treatment. (1) Objective: The paper presents the results of a feasibility and pilot study. The study is an internal part of a randomized controlled trail (RCT) of the effect of probiotic supplementation on psychometric, anthropometric, metabolic, and inflammatory parameters in adult patients with depressive disorders depending on the presence of metabolic syndrome. (2) Methods: The trial has a four-arm, parallel-group, prospective, randomized, double-blind, controlled design. Sixty participants received a probiotic preparation containing Lactobacillus helveticus Rosell®-52 and Bifidobacterium longum Rosell®-175 over 60 days. The feasibility of the study design was assessed, as well as the rates of recruitment, eligibility, consent, and study completion. The following were assessed: depressive, anxiety and stress symptoms, quality of life, blood pressure, body mass index and waist circumference, complete blood count with differential, serum levels of C-reactive protein, high-density lipoprotein cholesterol, triglycerides, fasting glucose, some secondary markers of inflammation and metabolic health, as well as noninvasive biomarkers of liver fibrosis (APRI and FIB-4). (3) Results: The study was found to be generally feasible. The eligibility rate was 52% of recruited participants with 80% completing the study protocol. No differences in sociodemographic or anthropometric factors or basic laboratory findings were found between the placebo and probiotic group at the start of the intervention period. Importantly, the proportion of recruited participants fulfilling the criteria of metabolic syndrome was too low. (4) Conclusions: Whilst the whole study protocol was feasible, some different timepoint procedures require modification. The major weakness of the recruitment methods was that the percentage of metabolic arms participants was insufficient. Overall, the full RCT design on probiotics in depression with vs. without metabolic syndrome was shown to be feasible with little modification.

show abstract

Safety and efficacy of probiotic supplementation in 8 types of inflammatory arthritis: A systematic review and meta-analysis of 34 randomized controlled trials

Cited by 18 publications

References 157 publications

Spondyloarthritis and the microbiota: Where are we now?

Spondyloarthritis and the microbiota: Where are we now?

The Role of the Microbiome in Connective-Tissue-Associated Interstitial Lung Disease and Pulmonary Vasculitis

PRO-DEMET Randomized Controlled Trial on Probiotics in Depression—Pilot Study Results

Contact Info

Product

Resources

About